NCT04013555View on ClinicalTrials.gov

The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

January 20, 2020

Primary Completion Date

August 14, 2024

Study Completion Date

August 14, 2024

Conditions
SchizophreniaSchizoaffective DisorderSchizophreniform Disorder
Interventions
DRUG

N-acetylcysteine (NAC)

Flavored effervescent formulation

DRUG

Placebo

Flavored effervescent formulation designed to mimic NAC

DRUG

Tryptophan

Oral slurry form

Trial Locations (1)

21228

Maryland Psychiatric Research Center (MPRC) ; the Treatment Research Program (TRP), Catonsville

All Listed Sponsors
lead

University of Maryland, Baltimore

OTHER

NCT04013555 - The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia | Biotech Hunter | Biotech Hunter